Q Therapeutics Receives Orphan Drug Designation for Transverse Myelitis
26. September 2018 06:00 ET
|
Q Therapeutics, Inc.
FDA DESIGNATION WOULD PROVIDE 7 YEARS OF MARKET EXCLUSIVITY UPON MARKET APPROVAL OF Q-CELLS® SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage...
Q Therapeutics Announces Joint Venture With REPROCELL
23. April 2018 05:00 ET
|
Q Therapeutics, Inc.
PARTNERSHIP WILL DEVELOP IPSC-DERIVED PRODUCTS TO TREAT CENTRAL NERVOUS SYSTEM DISEASES INVOLVING DEMYELINATION AND DEGENERATIONSALT LAKE CITY and YOKOHAMA, Japan, April 23, 2018 (GLOBE NEWSWIRE) --...
Q Therapeutics Announces Research Collaboration With REPROCELL
13. Dezember 2017 07:00 ET
|
Q Therapeutics, Inc.
SALT LAKE CITY and YOKOHAMA, Japan, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury,...